Back to Authors

Alva, Ajjai

https://orcid.org/0000-0002-1898-3522

Mayo Clinic

University of Michigan

Citations 21

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Michaelson, M. Dror , Nandagopal, Lakshminarayanan , George, Saby , Alva, Ajjai , Harrison, Michael R. , Sosman, Jeffrey A. , Bhayani, Sam B., Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Kyriakopoulos, Christos E. , LaGrange, Chad A. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, McDonald, Andrew , Mortazavi, Amir , Ponsky, Lee , Redman, Bruce G., Somer, Bradley G. , Wile, Geoffrey, Dwyer, Mary A., CGC, Hammond, Lydia J., Zuccarino-Catania, Griselda, Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Gore, John L. , Haas, Naomi B , Plimack, Elizabeth R. , Agarwal, Neeraj , Gallagher, Thomas H. , Hancock, Steven Lee , Lam, Elaine T. , Manley, Brandon J. , Pierorazio, Phillip , CGC

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1278-1285

10.6004/jnccn.2019.0054 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.